{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T18:37:14Z","timestamp":1694630234131},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2006,7,1]],"date-time":"2006-07-01T00:00:00Z","timestamp":1151712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11940-006-0023-9","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T20:16:24Z","timestamp":1181074584000},"page":"335-345","source":"Crossref","is-referenced-by-count":9,"title":["Leukemias and lymphomas: Treatment and prophylaxis of the central nervous system"],"prefix":"10.1007","volume":"8","author":[{"given":"Janet L.","family":"Franklin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Finlay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"23_CR1","first-page":"131","volume":"12","author":"WA Bleyer","year":"1985","unstructured":"Bleyer WA, Poplack DA: Prophylaxis and treatment of leukemia in the central nervous system and other sanctuaries. Semin Oncol 1985, 12:131\u2013148.","journal-title":"Semin Oncol"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1023\/A:1005963732481","volume":"38","author":"N Gokbuger","year":"1998","unstructured":"Gokbuger N, Hoeltzer D: Meningeosis leukaemica in adult acute lymphoblastic leukemia. J Neurol Oncol 1998, 38:167\u2013180.","journal-title":"J Neurol Oncol"},{"key":"23_CR3","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3109\/02841869609084002","volume":"35","author":"N Keldsen","year":"1996","unstructured":"Keldsen N, Michalski W, Bentzen SM, et al.: Risk factors for central nervous system involvement in non-Hodgkin\u2019s lymphoma. Acta Oncol 1996, 35:703\u2013708.","journal-title":"Acta Oncol"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S0950-3536(96)80050-3","volume":"9","author":"ID Horak","year":"1996","unstructured":"Horak ID, Kremer AB, Magrath IT: Management of histologically aggressive lymphomas with a high risk of CNS disease. Baillieres Clin Haematol 1996, 9:707\u2013727.","journal-title":"Baillieres Clin Haematol"},{"key":"23_CR5","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/sj.leu.2400702","volume":"11","author":"JE Van Dongen-Melman","year":"1997","unstructured":"Van Dongen-MelmanJE, De Groot A, Van DongenJJ, et al.: Cranial irradiation is the major cause of learning problems in children treated for leukemia and lymphoma: a comparative study. Leukemia 1997, 11:1197\u20132000. This is an older comparative study that well illustrates the long-term impact of cranial irradiation on survivors of leukemia and lymphoma.","journal-title":"Leukemia"},{"key":"23_CR6","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.1998.16.6.2070","volume":"16","author":"TB Haddy","year":"1998","unstructured":"Haddy TB, Adde MA, McCalla J, et al.: Late effects in long-term survivors of high-grade non-Hodgkin\u2019s lymphomas. J Clin Oncol 1998, 16:2070\u20132079.","journal-title":"J Clin Oncol"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1055\/s-2008-1043912","volume":"210","author":"A Claviez","year":"1998","unstructured":"Claviez A, Neubauer B, Link J, Scheppenheim R: Intracerebral hemorrhage as a late complication after CNS treatment of childhood lymphoma. Klin Padiatr 1998, 210:406\u2013408.","journal-title":"Klin Padiatr"},{"key":"23_CR8","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.V95.9.2770.009k16_2770_2775","volume":"95","author":"L Loning","year":"2000","unstructured":"Loning L, Zimmerman M, Reiter A, et al.: Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood 2000, 95:2770\u20132775.","journal-title":"Blood"},{"key":"23_CR9","volume-title":"Principles and Practice of Pediatric Oncology","author":"JF Margolin","year":"2005","unstructured":"Margolin JF, Poplack DG: Acute lymphoblastic leukemia. In Principles and Practice of Pediatric Oncology, edn 5. Philadelphia: Lippincott Williams and Wilkins; 2005.","edition":"edn 5"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<234::AID-AJH6>3.0.CO;2-B","volume":"62","author":"RL Sham","year":"1999","unstructured":"Sham RL, Phatak PD, Kouides PA, et al.: Hematologic neoplasia and the central nervous system. Am J Hematol 1999, 62:234\u2013238.","journal-title":"Am J Hematol"},{"key":"23_CR11","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2257.1989.tb00231.x","volume":"11","author":"T Sheehan","year":"1989","unstructured":"Sheehan T, Cuthbert RJG, Parker AC: Central nervous system involvement in haematological malignancies. Clin Lab Haematol 1989, 11:331\u2013338.","journal-title":"Clin Lab Haematol"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1002\/1097-0142(19870815)60:4<906::AID-CNCR2820600432>3.0.CO;2-V","volume":"60","author":"GAW Bruyn","year":"1987","unstructured":"Bruyn GAW, Zwetsloot CP, van NieuwkoopJA, et al.: Cranial nerve palsy as a presenting feature of secondary plasma cell leukemia. Cancer 1987, 60:906\u2013909.","journal-title":"Cancer"},{"key":"23_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V84.2.355.355","volume":"84","author":"D Pinkel","year":"1994","unstructured":"Pinkel D, Woo S: Prevention and treatment of meningeal leukemia in children. Blood 1994, 84:355\u2013366.","journal-title":"Blood"},{"key":"23_CR14","first-page":"674","volume":"42","author":"ME Nesbit","year":"1982","unstructured":"Nesbit ME, Sather H, Robinson LL, et al.: Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Cancer Res 1982, 42:674\u2013680.","journal-title":"Cancer Res"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1023\/A:1005903414734","volume":"38","author":"M Schrappe","year":"1998","unstructured":"Schrappe M, Reiter A, Riehm H: Prophylaxis and treatment of neoplastic meningeosis in childhood acute lymphoblastic leukemia. J Neurooncol 1998, 38:159\u2013165.","journal-title":"J Neurooncol"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1038\/sj.leu.2403924","volume":"19","author":"BES Gibson","year":"2000","unstructured":"Gibson BES, Wheatley K, Hann IM, et al.: Treatment strategy and long term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2000, 19:2130\u20132138.","journal-title":"Leukemia"},{"key":"23_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJM199808273390907","volume":"339","author":"CH Pui","year":"1998","unstructured":"Pui CH, Evans WE: Acute lymphoblastic leukemia. N Engl J Med 1998, 339:605\u2013615.","journal-title":"N Engl J Med"},{"key":"23_CR18","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1182\/blood.V99.8.2734","volume":"99","author":"M Duval","year":"2002","unstructured":"Duval M, Suciu S, Ferster A, et al.: Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organization for Research and Treatment of Cancer-Children\u2019s Leukemia group phase 3 trial. Blood 2002, 99:2734\u20132739.","journal-title":"Blood"},{"key":"23_CR19","doi-asserted-by":"publisher","first-page":"3809","DOI":"10.1182\/blood-2002-08-2454","volume":"101","author":"BC Bostrom","year":"2003","unstructured":"Bostrom BC, Sensel MR, Sather H, et al.: Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard risk acute lymphoblastic leukemia: a report from the Children\u2019s Cancer Group. Blood 2003, 101:3809\u20133817. This large randomized trial demonstrates the impact that systemic drug therapy has on EFS as it relates to CNS relapse rates.","journal-title":"Blood"},{"key":"23_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1111\/j.1365-2141.2005.05509.x","volume":"129","author":"CD Mitchell","year":"2005","unstructured":"Mitchell CD, Richards SM, Kinsey SE, et al.: Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukemia: results of the UK Medical Research Council ALL97 randomized trial. Brit J Haematol 2005, 129:734\u2013745.","journal-title":"Brit J Haematol"},{"key":"23_CR21","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(81)91849-3","volume":"8218","author":"ME Nesbit","year":"1981","unstructured":"Nesbit ME, Robison LL, Littman PS, et al.: Presymptomatic central nervous system therapy in previously untreated childhood acute lymphoblastic leukemia: comparison of 1800 rad and 2400 rad. A report from the Children\u2019s Cancer Study Group. Lancet 1981, 8218:461\u2013466.","journal-title":"Lancet"},{"key":"23_CR22","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.1991.9.6.1012","volume":"9","author":"WA Bleyer","year":"1991","unstructured":"Bleyer WA, Sather HN, Nickerson HJ, et al.: Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low risk childhood acute lymphoblastic leukemia: a report of the CCG 106 study by the Children\u2019s Cancer Group. J Clin Oncol 1991, 9:1012\u20131021.","journal-title":"J Clin Oncol"},{"key":"23_CR23","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1200\/JCO.1993.11.3.527","volume":"11","author":"DG Tubergen","year":"1993","unstructured":"Tubergen DG, Gilchrist GS, O\u2019Brien RT, et al.: Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features. J Clin Oncol 1993, 11:527\u2013537.","journal-title":"J Clin Oncol"},{"key":"23_CR24","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","volume":"338","author":"JB Nachman","year":"1998","unstructured":"Nachman JB, Sather HN, Sensel MG, et al.: Augmented post-induction therapy for children with high risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998, 338:1663\u20131671.","journal-title":"N Engl J Med"},{"key":"23_CR25","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1182\/blood.V86.6.2091.bloodjournal8662091","volume":"86","author":"J Cortes","year":"1995","unstructured":"Cortes J, O\u2019Brien SM, Pierce S, et al.: The value of high dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995, 86:2091\u20132097.","journal-title":"Blood"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1200\/JCO.2000.18.3.547","volume":"18","author":"HM Kantarjian","year":"2000","unstructured":"Kantarjian HM, O\u2019Brien S, Smith TL, et al.: Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphoblastic leukemia. J Clin Oncol 2000, 18:547\u2013561.","journal-title":"J Clin Oncol"},{"key":"23_CR27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood.V66.5.1062.1062","volume":"66","author":"CH Pui","year":"1985","unstructured":"Pui CH, Dahl GV, Kalwinsky DK, et al.: Central nervous system leukemia in children with acute nonlymphoblastic leukemia. Blood 1985, 66:1062\u20131067.","journal-title":"Blood"},{"key":"23_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1046\/j.1365-2141.1998.00677.x","volume":"101","author":"RF Stevens","year":"1998","unstructured":"Stevens RF, Hann IM, Wheatley K, et al.: Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council\u2019s 10th AML trial. Br J Haematol 1998, 101:130\u2013140.","journal-title":"Br J Haematol"},{"key":"23_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1182\/blood.V97.1.56","volume":"97","author":"WG Woods","year":"2001","unstructured":"Woods WG, Neudorf S, Gold S, et al.: A comparison of allogeneic bone marrow transplant, autologous bone marrow transplant, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001, 97:56\u201362.","journal-title":"Blood"},{"key":"23_CR30","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2001.19.10.2705","volume":"19","author":"U Creutzig","year":"2001","unstructured":"Creutzig U, Ritter J, Zimmermann M, et al.: Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Munster 93. J Clin Oncol 2001, 19:2705\u20132713.","journal-title":"J Clin Oncol"},{"key":"23_CR31","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/sj.leu.2403131","volume":"17","author":"BL Abbott","year":"2003","unstructured":"Abbott BL, Rubnitz JE, Tong X, et al.: Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution\u2019s experience. Leukemia 2003, 17:2090\u20132096.","journal-title":"Leukemia"},{"key":"23_CR32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/sj.leu.2401971","volume":"15","author":"MM Bisschop","year":"2001","unstructured":"Bisschop MM, Revesz T, Bierings M, et al.: Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia. Leukemia 2001, 15:46\u201349.","journal-title":"Leukemia"},{"key":"23_CR33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1200\/JCO.1988.6.3.495","volume":"6","author":"PA Cassileth","year":"1988","unstructured":"Cassileth PA, Sylvester LS, Bennett JM, et al.: High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol 1988, 6:495\u2013500.","journal-title":"J Clin Oncol"},{"key":"23_CR34","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1182\/blood.V87.5.1710.1710","volume":"87","author":"JF Bishop","year":"1996","unstructured":"Bishop JF, Matthews JP, Young GA, et al.: A randomized study of high dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710\u20131717.","journal-title":"Blood"},{"issue":"Suppl 1","key":"23_CR35","first-page":"S10","volume":"10","author":"RH Herzig","year":"1996","unstructured":"Herzig RH: High dose ara-C in older adults with acute leukemia. Leukemia 1996, 10(Suppl 1):S10-S11.","journal-title":"Leukemia"},{"key":"23_CR36","first-page":"577","volume":"82","author":"C Castagnola","year":"1997","unstructured":"Castagnola C, Nozza A, Corso A, et al.: The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997, 82:577\u2013580.","journal-title":"Haematologica"},{"key":"23_CR37","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1046\/j.1365-2141.2003.04134.x","volume":"120","author":"MS Cairo","year":"2003","unstructured":"Cairo MS, Sposto R, Perkins SL, et al.: Burkitt\u2019s and Burkitt-like lymphoma in children and adolescents: a review of the Children\u2019s Cancer Group experience. Brit J Haematol 2003, 120:660\u2013670.","journal-title":"Brit J Haematol"},{"key":"23_CR38","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2000.18.10.2017","volume":"18","author":"S Gururangan","year":"2000","unstructured":"Gururangan S, Sposto R, Cairo MS, et al.: Outcome of CNS disease at diagnosis in disseminated small noncleaved-cell lymphoma and B-cell leukemia: a Children\u2019s Cancer Group Study. J Clin Oncol 2000, 18:2017\u20132025.","journal-title":"J Clin Oncol"},{"key":"23_CR39","first-page":"358","volume":"27","author":"C Patte","year":"1997","unstructured":"Patte C, Michon J, Behrendt H, et al.: Results of the LMB 89 protocol for childhood B-cell lymphoma and leukemia (ALL). Study of the SFOP. Med Pediatr Oncol 1997, 27:358.","journal-title":"Med Pediatr Oncol"},{"key":"23_CR40","first-page":"3294","volume":"94","author":"A Reiter","year":"1999","unstructured":"Reiter A, Schrappe M, Tiemann M, et al.: Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy; a report of the Berlin-Frankfurt-Munster Group trial NHL BFM 90. Blood 1999, 94:3294\u20133306.","journal-title":"Blood"},{"key":"23_CR41","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2000.18.16.3018","volume":"18","author":"JT Sandlund","year":"2000","unstructured":"Sandlund JT, Murphy SB, Santana VM, et al.: CNS involvement in children with newly diagnosed non-Hodgkin\u2019s lymphoma. J Clin Oncol 2000, 18:3018\u20133024.","journal-title":"J Clin Oncol"},{"key":"23_CR42","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1200\/JCO.2005.02.2707","volume":"24","author":"B Burkhardt","year":"2006","unstructured":"Burkhardt B, Woessmann W, Zimmerman M, et al.: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol 2006, 24:491\u2013499.","journal-title":"J Clin Oncol"},{"key":"23_CR43","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/ajh.10262","volume":"72","author":"MS Cairo","year":"2003","unstructured":"Cairo MS, Sposto R, Hoover-Regan M, et al.: Childhood and adolescent large cell lymphoma: a review of the Children\u2019s Cancer Group experience. Am J Hematol 2003, 72:53\u201363.","journal-title":"Am J Hematol"},{"key":"23_CR44","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1200\/JCO.2005.11.075","volume":"23","author":"JH Laver","year":"2005","unstructured":"Laver JH, Kraveka JM, Hutchinson RE, et al.: Advanced stage large cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate dose methotrexate and high dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol 2005, 23:541\u2013547.","journal-title":"J Clin Oncol"},{"key":"23_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1023\/A:1005944622003","volume":"38","author":"S Blaney","year":"1998","unstructured":"Blaney S, Poplack D: New cytotoxic drugs for intrathecal administration. J Neurooncol 1998, 38:219\u2013223.","journal-title":"J Neurooncol"},{"key":"23_CR46","volume-title":"Childhood Acute Lymphoblastic Leukemia in Cancer Medicine","author":"PS Gaynon","year":"2006","unstructured":"Gaynon PS, Angiolillo AL, Franklin JL, Reaman GH: Childhood Acute Lymphoblastic Leukemia in Cancer Medicine, edn 7. Hamilton, Ontario: Holland-Frei; 2006.","edition":"edn 7"},{"key":"23_CR47","first-page":"113","volume":"11","author":"S Blaney","year":"1992","unstructured":"Blaney S, Balis F, Murphy R, et al.: A phase 1 study of intrathecal mafosfamide in patients with refractory meningeal malignancies. Proc Am Soc Clin Oncol 1992, 11:113.","journal-title":"Proc Am Soc Clin Oncol"},{"key":"23_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1023\/A:1005940405165","volume":"38","author":"I Slavc","year":"1998","unstructured":"Slavc I, Schuller E, Czech T, et al.: Intrathecal mafosfamide therapy for pediatric brain tumors with meningeal dissemination. J Neurooncol 1998, 38:213\u2013218.","journal-title":"J Neurooncol"},{"key":"23_CR49","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1023\/A:1025633704071","volume":"64","author":"I Slavc","year":"2003","unstructured":"Slavc I, Schuller E, Falger J, et al.: Feasibility of longterm intraventricular therapy with mafosfamide and etoposide: experience in 26 children with disseminated malignant brain tumors. J Neurooncol 2003, 64:239\u2013247.","journal-title":"J Neurooncol"},{"key":"23_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/JCO.2003.04.053","volume":"21","author":"S Blaney","year":"2003","unstructured":"Blaney S, Heideman R, Berg S, et al.: Phase 1 clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003, 21:143\u2013147.","journal-title":"J Clin Oncol"},{"key":"23_CR51","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1200\/JCO.1992.10.1.143","volume":"10","author":"S Berg","year":"1992","unstructured":"Berg S, Balis F, Zimm S, et al.: Phase I\/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J Clin Oncol 1992, 10:143\u2013148.","journal-title":"J Clin Oncol"},{"key":"23_CR52","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.1998.16.9.3000","volume":"16","author":"V Sandor","year":"1999","unstructured":"Sandor V, Stark-Vancs V, Peterson D, et al.: Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1999, 16:3000\u20133006.","journal-title":"J Clin Oncol"},{"key":"23_CR53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K, et al.: Results of intensive chemotherapy followed by hematopoietic stem cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001, 19:742\u2013749.","journal-title":"J Clin Oncol"},{"key":"23_CR54","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/sj.bmt.1703917","volume":"31","author":"T Cheng","year":"2003","unstructured":"Cheng T, Forsyth P, Chaudhry A, et al.: High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003, 31:679\u2013685.","journal-title":"Bone Marrow Transplant"},{"key":"23_CR55","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1023\/A:1019999830455","volume":"59","author":"H Pels","year":"2002","unstructured":"Pels H, Schulz H, Manke O, et al.: Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002, 59:213\u2013216.","journal-title":"J Neurooncol"},{"key":"23_CR56","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000072095","volume":"26","author":"H Pels","year":"2003","unstructured":"Pels H, Schultz H, Schlegel U, et al.: Treatment of CNS lymphoma with the anti-CD 20 antibody rituximab: experience with two cases and review of the literature. Onkologie 2003, 26:351\u2013354.","journal-title":"Onkologie"},{"key":"23_CR57","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2002-06-1636","volume":"101","author":"JL Rubenstein","year":"2003","unstructured":"Rubenstein JL, Combs D, Rosenberg J, et al.: Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003, 101:466\u2013468.","journal-title":"Blood"},{"key":"23_CR58","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1200\/JCO.2004.01.046","volume":"22","author":"L Bomgaars","year":"2004","unstructured":"Bomgaars L, Geyer JR, Franklin J, et al.: Phase 1 trial of intrathecal liposomal cytarabine in children with neoplastic meningitis. J Clin Oncol 2004, 22:3916\u20133921.","journal-title":"J Clin Oncol"},{"key":"23_CR59","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","volume":"17","author":"MJ Glantz","year":"1999","unstructured":"Glantz MJ, LaFollette S, Jaeckle KA, et al.: Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis. J Clin Oncol 1999, 17:3110\u20133116. This is a well-conducted, small randomized trial that evaluates a novel CNS drug therapy against a standard CNS drug therapy, with positive results.","journal-title":"J Clin Oncol"},{"key":"23_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<511::AID-CNCR33>3.0.CO;2-H","volume":"85","author":"AM Mosher","year":"1999","unstructured":"Mosher AM, Adamson PC, Gillespie AJ, et al.: Intraventricular concentration times time (C x T) methotrexate and cytarabine for patients with recurrent meningeal leukemia and lymphoma. Cancer 1999, 85:511\u2013516.","journal-title":"Cancer"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11940-006-0023-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0023-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-006-0023-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:28:51Z","timestamp":1652614131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11940-006-0023-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s11940-006-0023-9","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,7]]}}}